Skip to main content
Premium Trial:

Request an Annual Quote

GeneCentric Therapeutics/Tempus PurIST Pancreatic Cancer Test

GeneCentric Therapeutics' PurIST test for pancreatic cancer is now commercially available through Tempus for clinical use. PurIST is an RNA-expression test for identifying those patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) most likely to experience longer overall survival with standard-of-care FOLFIRINOX than patients with the basal PDAC subtype. PurIST is a laboratory-developed test validated by Tempus as part of its whole-transcriptome RNA sequencing platform.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.